A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan
-
Published:2022-07
Issue:1
Volume:90
Page:83-95
-
ISSN:0344-5704
-
Container-title:Cancer Chemotherapy and Pharmacology
-
language:en
-
Short-container-title:Cancer Chemother Pharmacol
Author:
Ishizawa KenichiORCID, Yokoyama Masahiro, Kato Harumi, Yamamoto Kazuhito, Makita Masanori, Ando Kiyoshi, Ueda Yasunori, Tachikawa Yoshimichi, Suehiro Youko, Kurosawa Mitsutoshi, Kameoka Yoshihiro, Nagai Hirokazu, Uoshima Nobuhiko, Ishikawa Takayuki, Hidaka Michihiro, Ito Yoshikiyo, Utsunomiya Atae, Fukushima Koji, Ogura Michinori
Abstract
Abstract
Purpose
This phase I/II clinical study was conducted to examine the safety, tolerability, pharmacokinetics, and efficacy of 10-min dosing of bendamustine in patients with previously untreated indolent B-cell non-Hodgkin lymphoma (iNHL) or mantle cell lymphoma (MCL) (Group 1) and patients with relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL) (Group 2).
Methods
Rituximab 375 mg/m2 was administered intravenously every 28 days to Group 1 patients on day 1 and every 21 days to Group 2 patients on day 1. Bendamustine 90 mg/m2/day was administered to the former on days 1 and 2; bendamustine 120 mg/m2/day was administered to the latter on days 2 and 3. Each regimen was delivered up to six cycles for both groups. The primary endpoints were safety and tolerability in Groups 1 and 2, respectively.
Results
Among 37 enrolled patients, safety was assessed in 36. In Group 1 (n = 30), 27 patients (90%) had follicular lymphoma. Adverse events (AEs) were observed in all 30 patients in Group 1. Dose-limiting toxicities were observed in two of six patients in Group 2. Common AEs included lymphocyte count decreased (86.7%, 100%). In Group 1, overall response and complete response rates were 93.1% (95% confidence interval [CI] 77.2–99.2%) and 75.9% (95% CI 56.5–89.7%), respectively. The Cmax and AUC of bendamustine tended to be higher in Group 2 than in Group 1.
Conclusions
This study showed that bendamustine is safe, well-tolerated and effective for patients with previously untreated iNHL, MCL or rrDLBCL. Pharmacokinetic data were equivalent to those obtained outside of Japan.
Registration numbers
Registration NCT03900377; registered April 3, 2019.
Funder
SymBio Pharmaceuticals Limited Sanofi Novartis AbbVie Bayer Takeda Pharmaceutical Company Celgene Ono Pharmaceutical Chugai Pharmaceutical Eisai IQVIA SRD MSD K.K. Otsuka Pharmaceutical Micron Janssen Kyowa Hakko Kirin Zenyaku Kogyo Incyte Mundipharma ADC AstraZeneca Bristol-Myers Squibb Daiichi-Sankyo Genmab HUYA Meiji Seika Pharma Nippon Shinyaku Pfizer Solasia Stemline Dainippon Sumitomo Pharma Yakult Astellas Pharma Amgen Takeda Teijin Pharma National Hospital Organization Chordia Bristol-Myers Minophagen JIMRO Otsuka Medical Device Celltrion Healthcare Verastem DenovoBiopharma
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference23 articles.
1. Blumel S, Goodrich A, Martin C, Dang NH (2008) Bendamustine: a novel cytotoxic agent for hematologic malignancies. Clin J Oncol Nurs 12:799–806. https://doi.org/10.1188/08.CJON.799-806 2. Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, Elliott G, Niemeyer CC (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14:309–317. https://doi.org/10.1158/1078-0432.CCR-07-1061 3. Ogura M, Uchida T, Taniwaki M, Ando K, Watanabe T, Kasai M, Matsumoto Y, Shimizu D, Ogawa Y, Ohmachi K, Yokoyama H, Tobinai K, Japanese Bendamustine Lymphoma Study G (2010) Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 101:2054–2058. https://doi.org/10.1111/j.1349-7006.2010.01633.x 4. Cheson BD, Leoni L (2011) Bendamustine: mechanism of action and clinical data. Clin Adv Hematol Oncol 9:1–11 5. Cheson BD, Wendtner CM, Pieper A, Dreyling M, Friedberg J, Hoelzer D, Moreau P, Gribben J, Knop S, Montillo M, Rummel M (2010) Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 10:21–27. https://doi.org/10.3816/CLML.2010.n.002
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|